Table 3. TEA trial: differences in DDD per 1000 patients of prescribed drugs (intervention vs control: 1605 included GPs).

	Absolute mean prescriptionduring follow-up in the ‘intervention group’ (DDD per 1000assisted population/day)	Absolute difference atfollow-up vs control group (change from baselineexpressed as DDD per 1000 assisted population/day)	Relative % variationvs control: m-ITT(95% CI)
Primary outcomes (arm 1: BPH)
finasteride+dutasteride	6.61	0.24	3.6% (−2.9 to 10.2%)
alfuzosin vs tamsulosin +terazosin †	0.71 (ratio)	−0.06	−8.5% (−16.9 to −0.7%)
Secondary outcomes (arm 1: BPH)
finasteride	3.60	0.05	1.4% (−6.5 to 9.5%)
dutasteride	3.00	0.18	5.8% (−2.6 to 14.3%)
alfuzosin	6.82	−0.11	−1.7% (−8.9 to 5.6%)
tamsulosin	7.92	0.28	3.7% (−3.1 to 10.4%)
terazosin	3.21	0.17	5.4% (−4.1 to 14.6%)
Primary outcomes (arm 2: osteoporosis)
alendronate	4.99	<0.01	0.1% (−7.3 to 7.5%)
risedronate	2.03	−0.11	−5.1% (−15.3 to 5.6%)
Secondary outcomes (arm 2: osteoporosis)
ibandronate	0.48	−0.11	−19.6% (−33.9 to −5.4%)
alendronate vs risedronate + ibandronate §	2.89 (ratio)	0.27	10.4% (−3.5 to 24.6%)
strontium ranelate	0.59	0.03	4.8% (−12.9 to 21.0%)
raloxifene	0.13	<0.01	0.4% (−26.9 to 27.5%)
calcium	1.83	−0.11	−5.4% (−15.6 to 5.4%)
vitamin D	1.72	−0.06	−3.5% (−12.4 to 5.3%)

^†56 physicians who had not prescribed tamsulosin or terazosin could not be included in the calculation since this is a ratio.

^§300 physicians who had not prescribed risedronate or ibandronate could not be included in the calculation since this is a ratio.